Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapansutrile in Type 2 Diabetes Mellitus
NCT06047262Phase 2Recruiting
- Start
- Jul 2024
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of dapansutrile in type 2 diabetes mellitus (T2DM) (2 arms). Primary endpoint: Change in Hemoglobin A1c at 26 weeks. Started Jul 2024; status: recruiting.
02
Drugs
dapansutrile
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06047262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06047262.